2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Chern En Chiang; Kwo Chang Ueng; Ting Hsing Chao; Tsung Hsien Lin; Yih Jer Wu; Kang Ling Wang; Shih Hsien Sung; Hung I. Yeh; Yi Heng Li; Ping Yen Liu; Kuan Cheng Chang; Kou Gi Shyu; Jin Long Huang; Cheng Dao Tsai; Huei Fong Hung; Ming En Liu; Tze Fan Chao; Shu Meng Cheng; Hao Min Cheng; Pao Hsien Chu; Wei Hsian Yin; Yen Wen Wu; Wen Jone Chen; Wen Ter Lai; Shing Jong Lin; San Jou Yeh; Juey Jen Hwang; Charles Jia Yin Hou

doi:10.1016/j.jacasi.2021.08.003

2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Chern En Chiang, Kwo Chang Ueng, Ting Hsing Chao, Tsung Hsien Lin, Yih Jer Wu, Kang Ling Wang, Shih Hsien Sung, Hung I. Yeh, Yi Heng Li, Ping Yen Liu, Kuan Cheng Chang, Kou Gi Shyu, Jin Long Huang, Cheng Dao Tsai, Huei Fong Hung, Ming En Liu, Tze Fan Chao, Shu Meng Cheng, Hao Min Cheng, Pao Hsien ChuWei Hsian Yin, Yen Wen Wu, Wen Jone Chen, Wen Ter Lai, Shing Jong Lin, San Jou Yeh, Juey Jen Hwang, Charles Jia Yin Hou

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.

Original language	English
Pages (from-to)	129-146
Number of pages	18
Journal	JACC: Asia
Volume	1
Issue number	2
DOIs	https://doi.org/10.1016/j.jacasi.2021.08.003
Publication status	Published - 2021 Sept

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacasi.2021.08.003

Cite this

Chiang, C. E., Ueng, K. C., Chao, T. H., Lin, T. H., Wu, Y. J., Wang, K. L., Sung, S. H., Yeh, H. I., Li, Y. H., Liu, P. Y., Chang, K. C., Shyu, K. G., Huang, J. L., Tsai, C. D., Hung, H. F., Liu, M. E., Chao, T. F., Cheng, S. M., Cheng, H. M., ... Hou, C. J. Y. (2021). 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. JACC: Asia, 1(2), 129-146. https://doi.org/10.1016/j.jacasi.2021.08.003

@article{a1e60a4e7b6340d89968956b941e3d56,

title = "2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes",

abstract = "Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.",

author = "Chiang, {Chern En} and Ueng, {Kwo Chang} and Chao, {Ting Hsing} and Lin, {Tsung Hsien} and Wu, {Yih Jer} and Wang, {Kang Ling} and Sung, {Shih Hsien} and Yeh, {Hung I.} and Li, {Yi Heng} and Liu, {Ping Yen} and Chang, {Kuan Cheng} and Shyu, {Kou Gi} and Huang, {Jin Long} and Tsai, {Cheng Dao} and Hung, {Huei Fong} and Liu, {Ming En} and Chao, {Tze Fan} and Cheng, {Shu Meng} and Cheng, {Hao Min} and Chu, {Pao Hsien} and Yin, {Wei Hsian} and Wu, {Yen Wen} and Chen, {Wen Jone} and Lai, {Wen Ter} and Lin, {Shing Jong} and Yeh, {San Jou} and Hwang, {Juey Jen} and Hou, {Charles Jia Yin}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = sep,

doi = "10.1016/j.jacasi.2021.08.003",

language = "English",

volume = "1",

pages = "129--146",

journal = "JACC: Asia",

issn = "2772-3747",

publisher = "Elsevier Inc.",

number = "2",

}

Chiang, CE, Ueng, KC, Chao, TH, Lin, TH, Wu, YJ, Wang, KL, Sung, SH, Yeh, HI, Li, YH , Liu, PY, Chang, KC, Shyu, KG, Huang, JL, Tsai, CD, Hung, HF, Liu, ME, Chao, TF, Cheng, SM, Cheng, HM, Chu, PH, Yin, WH, Wu, YW, Chen, WJ, Lai, WT, Lin, SJ, Yeh, SJ, Hwang, JJ & Hou, CJY 2021, '2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes', JACC: Asia, vol. 1, no. 2, pp. 129-146. https://doi.org/10.1016/j.jacasi.2021.08.003

TY - JOUR

T1 - 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

AU - Chiang, Chern En

AU - Ueng, Kwo Chang

AU - Chao, Ting Hsing

AU - Lin, Tsung Hsien

AU - Wu, Yih Jer

AU - Wang, Kang Ling

AU - Sung, Shih Hsien

AU - Yeh, Hung I.

AU - Li, Yi Heng

AU - Liu, Ping Yen

AU - Chang, Kuan Cheng

AU - Shyu, Kou Gi

AU - Huang, Jin Long

AU - Tsai, Cheng Dao

AU - Hung, Huei Fong

AU - Liu, Ming En

AU - Chao, Tze Fan

AU - Cheng, Shu Meng

AU - Cheng, Hao Min

AU - Chu, Pao Hsien

AU - Yin, Wei Hsian

AU - Wu, Yen Wen

AU - Chen, Wen Jone

AU - Lai, Wen Ter

AU - Lin, Shing Jong

AU - Yeh, San Jou

AU - Hwang, Juey Jen

AU - Hou, Charles Jia Yin

PY - 2021/9

Y1 - 2021/9

N2 - Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.

AB - Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.

UR - http://www.scopus.com/inward/record.url?scp=85132144478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132144478&partnerID=8YFLogxK

U2 - 10.1016/j.jacasi.2021.08.003

DO - 10.1016/j.jacasi.2021.08.003

M3 - Review article

AN - SCOPUS:85132144478

SN - 2772-3747

VL - 1

SP - 129

EP - 146

JO - JACC: Asia

JF - JACC: Asia

IS - 2

ER -

2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this